哌拉西林引起的骨髓抑制：一例报告。
Piperacillin induced bone marrow suppression: a case report.
作者信息
Kumar Ashish, Choudhuri Gourdas, Aggarwal Rakesh
机构信息
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.
出版信息
BMC Clin Pharmacol. 2003 Jun 5;3:2. doi: 10.1186/1472-6904-3-2.
Abstract
BACKGROUND
Piperacillin (and piperacillin/tazobactam) is a commonly prescribed antibiotic and is generally considered safe. We report a case of piperacillin induced bone marrow suppression.
CASE PRESENTATION
A 19-year-old boy was being treated with piperacillin followed by piperacillin/tazobactam for infected pancreatic pseudocyst. After 21 days of treatment, he developed neutropenia and thrombocytopenia. These reversed promptly after stopping piperacillin/tazobactam. The time course of events suggested that piperacillin was the cause of bone marrow suppression in this patient.
CONCLUSION
Bone marrow suppression is a serious adverse effect of piperacillin, which should be kept in mind while treating patients with this drug.
摘要
背景
哌拉西林（以及哌拉西林/他唑巴坦）是一种常用的抗生素，通常被认为是安全的。我们报告一例哌拉西林引起的骨髓抑制病例。
病例介绍
一名19岁男孩因感染性胰腺假性囊肿接受哌拉西林治疗，随后使用哌拉西林/他唑巴坦。治疗21天后，他出现了中性粒细胞减少和血小板减少。停用哌拉西林/他唑巴坦后，这些症状迅速逆转。事件的时间进程表明，哌拉西林是该患者骨髓抑制的原因。
结论
骨髓抑制是哌拉西林的一种严重不良反应，在使用该药物治疗患者时应予以关注。
相似文献
1
Piperacillin induced bone marrow suppression: a case report.
BMC Clin Pharmacol. 2003 Jun 5;3:2. doi: 10.1186/1472-6904-3-2.
2
Severe bone marrow suppression and hepatic dysfunction caused by piperacillin/tazobactam.
Scand J Infect Dis. 2013 Nov;45(11):885-7. doi: 10.3109/00365548.2013.805426. Epub 2013 Jul 5.
3
Piperacillin-induced thrombocytopenia reversed by high-flux hemodialysis in an uremic patient.
Hemodial Int. 2012 Oct;16 Suppl 1:S50-3. doi: 10.1111/j.1542-4758.2012.00745.x.
4
Piperacillin and vancomycin induced severe thrombocytopenia in a hospitalized patient.
Platelets. 2011;22(4):294-301. doi: 10.3109/09537104.2010.549973. Epub 2011 Feb 10.
5
Reversible bone marrow depression by high-dose piperacillin/tazobactam.
Br J Haematol. 1996 Dec;95(4):611-2. doi: 10.1046/j.1365-2141.1996.d01-1952.x.
6
Rapid-Onset Thrombocytopenia Following Piperacillin-Tazobactam Reexposure.
Pharmacotherapy. 2015 Dec;35(12):e326-30. doi: 10.1002/phar.1675.
7
A case of probable piperacillin/tazobactam-induced bone marrow suppression in a pregnant woman.
Eur J Hosp Pharm. 2019 May;26(3):170-172. doi: 10.1136/ejhpharm-2017-001243. Epub 2017 Oct 21.
8
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
Clin Microbiol Infect. 2006 Mar;12(3):212-6. doi: 10.1111/j.1469-0691.2005.01297.x.
9
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
J Antimicrob Chemother. 2007 Aug;60(2):370-6. doi: 10.1093/jac/dkm130. Epub 2007 Jun 6.
10
Rapid-onset piperacillin-tazobactam induced thrombocytopenia.
J Pharm Pract. 2015 Apr;28(2):204-6. doi: 10.1177/0897190014566302. Epub 2015 Jan 21.
引用本文的文献
1
Risk of Neutropenia in Adults Treated with Piperacillin-Tazobactam or Cefazolin: A Retrospective Cohort Study.
Can J Hosp Pharm. 2022 Jul 4;75(3):186-192. doi: 10.4212/cjhp.3161. eCollection 2022 Summer.
2
Probable Vancomycin Induced Neutropenia: A Case Report.
Cureus. 2019 Jul 22;11(7):e5199. doi: 10.7759/cureus.5199.
3
A case of probable piperacillin/tazobactam-induced bone marrow suppression in a pregnant woman.
Eur J Hosp Pharm. 2019 May;26(3):170-172. doi: 10.1136/ejhpharm-2017-001243. Epub 2017 Oct 21.
4
Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults.
Turk J Haematol. 2018 Nov 13;35(4):290-295. doi: 10.4274/tjh.2018.0127. Epub 2018 Jun 1.
5
Tazobactam and piperacillin-induced thrombocytopenia: A case report.
Exp Ther Med. 2016 Apr;11(4):1223-1226. doi: 10.3892/etm.2016.3062. Epub 2016 Feb 9.
6
Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test.
Ups J Med Sci. 2013 Nov;118(4):279-84. doi: 10.3109/03009734.2013.838811.
7
Piperacillin/tazobactam Induced Myelosuppression.
J Clin Med Res. 2009 Apr;1(1):53-5. doi: 10.4021/jocmr2009.03.1227. Epub 2009 Mar 24.
8
Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis.
Indian J Pharmacol. 2011 Sep;43(5):609-10. doi: 10.4103/0253-7613.84986.
9
Systematic review of piperacillin-induced neutropenia.
Drug Saf. 2007;30(4):295-306. doi: 10.2165/00002018-200730040-00002.
10
Drug-induced thrombocytopenia: a population study.
Drug Saf. 2006;29(8):713-21. doi: 10.2165/00002018-200629080-00008.
本文引用的文献
1
Thrombotic thrombocytopenia purpura caused by piperacillin successfully treated with plasma infusion.
Ann Hematol. 2000 Oct;79(10):593-5. doi: 10.1007/s002770000195.
2
Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis.
Infection. 1999 Nov-Dec;27(6):355-6. doi: 10.1007/s150100050042.
3
Haemolytic anaemia following treatment with piperacillin in a patient with cystic fibrosis.
J Antimicrob Chemother. 1999 Mar;43(3):435-6. doi: 10.1093/jac/43.3.435.
4
Immune thrombocytopenia caused by piperacillin/tazobactam.
Clin Infect Dis. 1998 Sep;27(3):650-1. doi: 10.1086/517143.
5
Reversible bone marrow depression by high-dose piperacillin/tazobactam.
Br J Haematol. 1996 Dec;95(4):611-2. doi: 10.1046/j.1365-2141.1996.d01-1952.x.
6
Life-threatening neutropenia secondary to piperacillin/tazobactam therapy.
Clin Infect Dis. 1995 Oct;21(4):1047-8. doi: 10.1093/clinids/21.4.1047-a.
7
Beta-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease.
Am J Med. 1993 Mar;94(3):251-6. doi: 10.1016/0002-9343(93)90056-u.
8
[A case of piperacillin induced leucopenia whose CFU-C derived colony was inhibited in vitro by the coexisting addition of drug, serum, and mononuclear cells].
Rinsho Ketsueki. 1984 Feb;25(2):197-202.
9
Piperacillin therapy for serious bacterial infections.
Am J Med. 1980 Aug;69(2):255-61. doi: 10.1016/0002-9343(80)90386-1.
10
Clinical evaluation of the therapeutic efficacy and tolerability of piperacillin.
Antimicrob Agents Chemother. 1982 Jul;22(1):10-4. doi: 10.1128/AAC.22.1.10.
Zotero 插件